A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer
Key facts
- Who runs it
- University Health Network, Toronto
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- Oct 2023
- Ended
- Jan 2025
- Type of study
- Interventional
- Treatments tested
- Adaptive Radiation Therapy
- Record updated
- 19 March 2024
- Why it stopped
- This study is being closed. The protocol may be reviewed and consolidated under a new study currently in development.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Histologic diagnosis of adenocarcinoma of the prostate after radical prostatectomy:; Clinical stage pT3, pT4, or pT2 with positive margin; OR,; any p-stage with persistently elevated post-operative PSA > 0.05ng/mL; OR,; a delayed rise in PSA post-operative
- Histologic diagnosis of transitional cell carcinoma of the bladder with intact bladder and:; Clinical stage cT2, cT3, cT4, and N0 or N1
Who cannot take part
- Prior pelvic radiotherapy
- Previous cytotoxic chemotherapy
- Inflammatory bowel disease or other contraindications to radiotherapy
- Evidence of systemic metastases on imaging
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Radical radiation therapy for prostate cancer is a common treatment that has shown to improve clinical outcomes in a post-operative setting. However, radiation therapy after surgery poses a greater risk for bladder and rectum injury for patients with prostate or bladder cancer. For prostate cancer patients, the risk is further amplified when pelvic nodes are part of the target irradiated volume. For bladder cancer patients, the risk of injury increases when more of the bladder is part of the target volume. Using an adaptive radiation therapy approach allows for correcting any shifts in the target volume. ART approach uses images from treatment to adapt the treatment plan. This study will use Adaptive Radiation Therapy for patients who receive pelvic nodal radiotherapy for either prostate or bladder cancer. Their treatment plans will adapted using MRI scans and CBCT scans taken during their first week of radiotherapy to account for any shifts in the target volume. The purpose of this study is to evaluate the feasibility of ART approach and its and on treatment plan quality metrics for pelvic radiotherapy. Acute and late toxicities will also be evaluated. 40 participants (minimum of 10 bladder cancer patients) will be enrolled. The participants will be followed for a period of 5 years post radiation therapy, during which they will have PSA as per standard practice, along with follow-up questionnaires (EPIC for prostate cancer patients and BUSS for bladder cancer patients).
The group in the trial
- Adaptive Radiation TherapyTreatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 19 March 2024